FASN and metabolic dysfunction-associated steatohepatitis: Importantly, individuals with NASH receiving 50 mg of the oral FASN inhibitor TVB-2640 for 12 weeks showed lower steady-state SAFA, whereas PUFAs in TAG composition were substantially higher compared to patients receiving placebo (Fig. 2c).